

# Transdermal Nanomedicine: Pharmaceutical Advances for Controlled and Painless Drug Delivery

Nittala Seshasarvani<sup>1\*</sup>, V Arun Reddy<sup>2</sup>, Srinivasarao Mande<sup>3</sup>, Lodhi Rubeeya<sup>3</sup>, Arslan Sarmad<sup>3</sup>,  
Y.Ganesh Kumar<sup>1</sup>

<sup>1</sup>Bharat Institute of Pharmacy, Mangalpally (V), Ibrahimpatnam (M), R.R. Dist - 501510. Telangana, India

<sup>2</sup>Bharat School of Pharmacy, Mangalpally, Ibrahimpatnam, R R Dist, Telangana, India, Pin-501510

<sup>3</sup>Chaitanya (Deemed to be a university), Hyderabad, Telangana, India, Pin-500075

\*Corresponding Author E-mail: nittalasarvani@gmail.com

---

## Abstract:

Transdermal drug delivery (TDD) offers a non-invasive, patient-friendly alternative to oral and injectable therapies by bypassing hepatic first-pass metabolism and providing controlled, sustained plasma levels. However, the stratum corneum represents a formidable barrier limiting drug permeation, restricting TDD to a narrow subset of therapeutically suitable agents and necessitating innovative delivery strategies. Nanomedicine has revolutionized transdermal drug delivery through nanocarrier platforms—including liposomes, niosomes, transfersomes, ethosomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, and nanoemulsions—that enhance skin penetration, improve bioavailability, and enable targeted drug delivery. These nanocarriers exploit multiple complementary mechanisms, including lipid-mediated barrier modulation, transiently increased skin hydration, preferred routing through intercellular and appendageal pathways, and sustained, controlled release from the carrier matrix. Nanocarrier physicochemical properties—such as size, surface charge, elasticity, and composition—can be precisely engineered to optimize skin deposition, retention, and systemic absorption of diverse drug classes, ranging from small molecules to peptides, proteins, and nucleic acids. Clinical applications span pain management, hormone replacement therapy, cardiovascular disorders, and vaccine delivery, with demonstrated improvements in efficacy, reduced dosing frequency, and enhanced patient compliance compared to conventional formulations. Integration with advanced enhancement techniques—including microneedles, iontophoresis, sonophoresis, and stimuli-responsive triggers—further augments therapeutic outcomes and enables precision dosing. Challenges in large-scale manufacturing, formulation stability, batch-to-batch reproducibility, and regulatory harmonization persist, requiring continued innovation in formulation science and quality assurance. Future directions emphasize smart, stimuli-responsive nanocarriers, AI-driven optimization, personalized transdermal therapy, wearable device integration for real-time monitoring, and hybrid biomimetic systems. Collectively, transdermal nanomedicine represents a transformative paradigm, offering controlled, painless, and patient-centric drug delivery while expanding the therapeutic scope of previously unsuitable compounds—positioning nanomedicines as a cornerstone of next-generation pharmaceutical advancement and precision therapeutics.

**Keywords:** Transdermal Drug Delivery, Nanocarriers, Nanomedicine, Skin Penetration, Controlled Release, Liposomes, Nanostructured Lipid Carriers, Polymeric Nanoparticles, Bioavailability, Transdermal Patches, Microneedles, Pharmacokinetics, Targeted Delivery, Patient Compliance, Theranostic Nanomedicine

---

Received: Jan. 13, 2026

Revised: Feb. 26, 2026

Accepted: March. 25, 2026

Published: April. 08, 2026

DOI: <https://doi.org/10.64474/3107-6386.Vol2.Issue1.4>

<https://ijcps.nknpub.com/1/issue/archive>

*This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)*

## 1. Introduction

Neurodegenerative and central nervous system (CNS) disorders—including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and various forms of brain tumors—remain some of the most challenging conditions to treat due to the intrinsic complexity of the brain and its limited regenerative capacity. A major bottleneck in the effective management of these disorders is the blood–brain barrier (BBB), a highly specialized structural and biochemical interface that protects the brain from toxins, pathogens, and fluctuations in plasma composition<sup>1-2</sup>. While essential for maintaining neural homeostasis, this barrier severely restricts the entry of most therapeutic agents, with more than 98% of small molecules and nearly all biologics failing to reach therapeutic concentrations within the CNS. Conventional drug delivery systems often fall short in overcoming this barrier due to poor permeability, rapid systemic clearance, and off-target toxicity. In this landscape, pharmaceutical nanotechnology has emerged as a transformative strategy capable of enhancing drug transport across the BBB through mechanisms such as surface modification, receptor-mediated targeting, and controlled release. This review aims to provide a comprehensive understanding of BBB-targeted nanotechnological approaches, outlining their mechanistic basis, therapeutic potential, and translational relevance<sup>3-4</sup>. The scope encompasses the biological complexity of the BBB, design considerations for nano-based therapeutics, current preclinical and clinical progress, and prospects for overcoming neurological disease barriers.

Figure 1




Figure 1: Schematic Overview of the Blood–Brain Barrier and Nanocarrier Entry Routes

## **2. Anatomy and Physiology of the Blood–Brain Barrier**

The blood–brain barrier is formed by a dynamic multicellular neurovascular unit comprising brain microvascular endothelial cells, pericytes, astrocytic end-feet, and supporting basement membrane components. Endothelial cells serve as the structural backbone of the BBB, distinguished by minimal pinocytotic activity and the presence of tight junction proteins such as claudin-5, occludin, and junctional adhesion molecules, which collectively maintain barrier integrity and restrict paracellular transport<sup>5-6</sup>. Pericytes regulate endothelial stability, angiogenesis, and permeability, while astrocytes modulate nutrient transport and reinforce the biochemical environment required for neuronal function. Multiple transport pathways coordinate the regulated movement of molecules across the BBB, including passive diffusion for lipophilic small molecules, carrier-mediated transport for glucose and amino acids, and receptor-mediated or adsorptive transcytosis for larger biomolecules. In pathological conditions such as Alzheimer’s disease, Parkinson’s disease, glioblastoma, and ischemic stroke, BBB integrity is compromised due to inflammation, oxidative stress, vascular dysfunction, and altered tight junction expression. Such disruptions can lead to impaired homeostasis but may also provide therapeutic windows for targeted drug delivery. Understanding these physiological and pathological mechanisms is crucial for the rational design of nanocarriers capable of safely and effectively navigating the BBB<sup>6-7</sup>.

## **3. Barriers to CNS Drug Delivery**

Delivering therapeutics to the central nervous system (CNS) is notoriously challenging due to the restrictive nature of the blood–brain barrier and the unique physiology of brain tissue. Only a very limited subset of small, lipophilic molecules can passively diffuse across the BBB, while large biologics—such as peptides, proteins, nucleic acids, and antibodies—are almost entirely excluded. Efflux transporters, including P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-associated proteins (MRPs), further reduce drug accumulation by actively pumping xenobiotics back into the bloodstream. Even when therapeutic agents manage to cross the barrier, they often encounter enzymatic degradation by metabolic enzymes localized on endothelial cells or within the brain parenchyma<sup>8-9</sup>. Additional physiological constraints compound the challenge: the dense and highly structured brain extracellular matrix hinders drug diffusion, while the immune-privileged nature of the CNS limits inflammatory responses but also restricts immune-mediated therapeutic strategies. Together, these barriers underscore the need for advanced delivery platforms capable of improving penetration, retention, and therapeutic efficacy within the CNS<sup>10</sup>.

## **4. Nanotechnology-Based Strategies for BBB Targeting**

Nanotechnology has opened new frontiers in CNS therapeutics by enabling engineered platforms that can navigate, bypass, or actively exploit BBB transport pathways. These carriers offer tunable physicochemical properties, enhanced stability, targeted delivery, and controlled release, making them powerful tools for improving drug bioavailability in the brain<sup>11</sup>.

### **4.1 Polymeric Nanoparticles**

Polymeric nanoparticles—including PLGA-based systems, PEGylated carriers, and chitosan-derived nanostructures—are among the most widely explored platforms for CNS targeting. Their tunable degradation rates, high drug-loading capacity, and ability to protect sensitive therapeutics from enzymatic breakdown make them ideal for brain delivery. Surface functionalization with targeting

ligands such as transferrin, lactoferrin, folate, peptides, or antibodies enables receptor-mediated transcytosis, significantly enhancing BBB penetration. These systems are especially useful for delivering hydrophobic drugs, nucleic acids, and neuroprotective agents<sup>12</sup>.

#### **4.2 Lipid-Based Nanocarriers**

Lipid-based systems—including conventional liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs)—mimic biological membranes and offer excellent biocompatibility. Their ability to encapsulate both hydrophilic and lipophilic drugs makes them versatile for CNS applications. More recently, lipid nanoparticles (LNPs), popularized by mRNA vaccines, have been engineered to deliver RNA therapeutics across the BBB using ionizable lipids and targeted surface modifications. These platforms are particularly promising for gene silencing, gene editing, and protein replacement therapies in neurodegenerative diseases<sup>13</sup>.

#### **4.3 Inorganic Nanocarriers**

Inorganic nanoparticles—including gold nanoparticles, mesoporous silica nanoparticles, and superparamagnetic iron oxide nanoparticles—offer unique properties such as optical responsiveness, magnetic maneuverability, and high surface area for drug loading. Their intrinsic imaging capabilities enable real-time tracking and theranostic applications, which are highly valuable in CNS disorders like glioblastoma. However, their clinical translation depends heavily on optimizing biodegradability and minimizing long-term toxicity, often achieved through advanced surface modifications<sup>14</sup>.

#### **4.4 Biomimetic and Cell-Derived Nanocarriers**

Biomimetic nanocarriers leverage nature's own transport systems to improve BBB traversal. Exosomes—endogenous nanosized vesicles involved in intercellular communication—naturally cross the BBB and are being explored as carriers for siRNA, miRNA, and small molecules. Another emerging strategy uses cell membrane-coated nanoparticles, in which red blood cell, leukocyte, or platelet membranes provide immune evasion, prolonged circulation, and enhanced targeting to inflamed or diseased brain regions. These systems combine the advantages of synthetic nanotechnology with the biological sophistication of natural vesicles<sup>15</sup>.

#### **4.5 Hybrid Nanoplatforms**

Hybrid nanocarriers integrate multiple materials—such as polymer–lipid combinations or metal–polymer architectures—to achieve complementary functionalities within a single platform. These multifunctional systems can simultaneously deliver drugs, genes, and imaging agents, facilitating both therapy and diagnosis (theranostics). Their modular design allows precise control over targeting, release kinetics, and BBB interaction mechanisms, making them highly adaptable for complex CNS conditions requiring combination therapy or real-time monitoring<sup>16</sup>.

### **5. BBB Targeting Strategies**

Overcoming the transport limitations of the blood–brain barrier requires strategic exploitation of its natural physiological pathways, and nanocarriers have been engineered to engage these routes with high precision. Receptor-mediated transcytosis (RMT) remains one of the most widely used approaches, leveraging receptors such as transferrin, lactoferrin, insulin, and low-density lipoprotein (LDL) to

shuttle therapeutic-loaded nanoparticles across endothelial cells. Nanocarriers functionalized with monoclonal antibodies or ligand mimetics can bind these receptors with high affinity, enabling efficient and selective BBB penetration. Carrier-mediated transport (CMT) represents another targeted avenue, where nanoparticles are designed to interact with nutrient transporters—particularly glucose, amino acid, and peptide carriers—to hijack endogenous transport mechanisms for drug delivery<sup>17-18</sup>. Beyond receptor-specific pathways, adsorptive-mediated transcytosis (AMT) exploits the electrostatic attraction between cationic nanoparticle surfaces and the negatively charged endothelial membrane, promoting nonspecific yet effective internalization. Physical methods further expand the BBB-targeting toolkit: focused ultrasound (FUS) enables temporary, localized BBB opening when used alongside microbubbles, while magnetic targeting utilizes iron oxide nanoparticles guided by external magnetic fields to accumulate therapeutics at precise brain regions. An alternative noninvasive route is intranasal nanocarrier delivery, which bypasses the BBB altogether by utilizing the olfactory and trigeminal pathways. Formulations incorporating mucoadhesive polymers significantly enhance retention and improve direct nose-to-brain transport, offering a patient-friendly strategy for CNS drug delivery<sup>19-20</sup>.

## 6. Nanocarrier Applications in Neurotherapeutics

Nanotechnology continues to revolutionize CNS drug delivery by enabling disease-specific, targeted, and multifunctional therapeutic interventions. In Alzheimer's disease, nanocarriers are used to enhance the brain delivery of anti-amyloid agents, antioxidants, cholinesterase inhibitors, and emerging RNA-based therapeutics. Polymeric, lipid, and metal-based platforms have shown promise in reducing amyloid plaque burden, mitigating oxidative stress, and improving synaptic function. In Parkinson's disease, nanoparticles facilitate the sustained delivery of dopamine agonists, neuroprotective molecules, gene-silencing agents, and mitochondrial modulators, helping to address both motor and non-motor symptoms<sup>21-22</sup>. Glioblastoma, one of the most treatment-resistant brain tumors, benefits from targeted nanoplatfoms that combine chemotherapy, photothermal therapy, immunomodulation, and imaging guidance to improve tumor specificity and reduce systemic toxicity. In stroke therapy, nanocarriers enable rapid delivery of thrombolytics, anti-inflammatory agents, neuroprotectants, and antioxidant therapies, supporting neuronal survival and functional recovery after ischemic or hemorrhagic injury. Across neurological disorders, nanotechnology also facilitates the delivery of complex biologics—including peptides, monoclonal antibodies, siRNA, miRNA, mRNA, and CRISPR components—by protecting these molecules from degradation and enhancing their penetration into deep brain regions. Collectively, these applications highlight the transformative potential of nanomedicine in reshaping treatment outcomes for diverse neurodegenerative and CNS diseases<sup>23-24</sup>.

## 7. Pharmacokinetics, Biodistribution, and Safety

Understanding the pharmacokinetics and biodistribution of nanocarriers designed for CNS delivery is crucial, yet highly challenging due to the restrictive physiology of the blood–brain barrier. Traditional ADME paradigms often fail to accurately predict the behavior of nanosystems, as particle size, surface chemistry, charge, and protein corona formation significantly influence circulation time and BBB penetration. Tracking nanocarriers *in vivo* requires advanced analytical and imaging techniques, including fluorescence, MRI, PET, and radiolabeling approaches that allow real-time monitoring of their transport and accumulation within brain tissues. However, long-term toxicity remains a major concern—some nanomaterials may accumulate within the brain or peripheral organs, especially if they exhibit slow biodegradation rates, leading to potential neurotoxicity or systemic burden. Additionally, interactions between nanocarriers and the immune system can trigger unwanted responses such as

microglial activation, cytokine release, and neuroinflammation, threatening both safety and therapeutic efficacy<sup>25-26</sup>. Addressing these pharmacokinetic and toxicological complexities is essential to ensure that CNS nanomedicine achieves clinical translation without compromising patient safety.

## 8. Preclinical Models and Evaluation Techniques

Rigorous preclinical evaluation is critical for assessing the therapeutic performance and safety of BBB-targeted nanocarriers, and this relies on a combination of *in vitro* and *in vivo* models. *In vitro* BBB systems, such as Transwell assays, co-culture models, and advanced microfluidic BBB-on-chip platforms, allow controlled assessment of permeability, transport mechanisms, and endothelial barrier integrity under physiologically relevant conditions. These models enable rapid screening but require confirmation in *in vivo* models, where rodents remain the most widely used due to their cost-effectiveness and well-characterized neurobiology<sup>28-29</sup>. Zebrafish models provide real-time optical transparency for studying nanoparticle biodistribution, while non-human primates offer the closest approximation to human BBB physiology for late-stage validation. To evaluate the CNS delivery efficiency and therapeutic impact of nanocarriers, researchers employ a range of imaging modalities—including MRI, PET, CT, and fluorescence imaging—to track nanoparticle localization and therapeutic payload distribution. Concurrently, the use of biomarkers and functional endpoints, such as cognitive performance, motor coordination, inflammatory markers, and neuronal survival indices, provides insight into both therapeutic efficacy and potential neurotoxicity. Together, these evaluation strategies create a comprehensive framework for advancing nanocarrier-based neurotherapeutics toward clinical readiness<sup>30-31</sup>.

## 9. Challenges and Limitations

Despite remarkable progress in BBB-targeted nanomedicine, several challenges continue to limit clinical translation. One of the biggest barriers is the poor translatability of animal model data to humans, as rodent and even primate BBB physiology often fails to fully replicate human neurovascular complexity. This mismatch results in inconsistent therapeutic outcomes when moving from preclinical to clinical stages. Manufacturing poses another major obstacle: achieving scalable, reproducible, and GMP-compliant production of complex nanocarriers—especially multi-layered or biomimetic systems—remains technically demanding and costly<sup>32-33</sup>. Regulatory pathways further complicate development, as agencies require detailed characterization of nanoparticle composition, biodistribution, long-term safety, and degradation profiles, creating extensive approval timelines. Additionally, the heterogeneity of BBB permeability across patients and disease states introduces variability in therapeutic responses, making it difficult to establish standardized dosing strategies. These limitations highlight the need for better models, more robust manufacturing frameworks, and harmonized regulatory guidelines to unlock the full clinical potential of BBB-targeted nanotechnologies<sup>34-35</sup>.

## 10. Future Perspectives

Looking ahead, the landscape of BBB-focused nanomedicine is poised for major transformation driven by innovations across nanotechnology, computational science, and bioengineering. AI-driven design is rapidly emerging as a powerful tool for predicting nanoparticle–BBB interactions, optimizing physicochemical properties, and accelerating lead candidate selection. The rise of personalized neuro-nanomedicine promises patient-specific formulations that account for individual differences in genetics, pathology, and BBB integrity<sup>36-37</sup>. Meanwhile, smart and stimuli-responsive nanocarriers capable of “on-demand” release—triggered by pH, enzymes, magnetic fields, or external energy sources—

represent the next wave of precision CNS therapeutics. Advances in organ-on-chip and humanized BBB models offer unprecedented platforms for studying nanoparticle transport under physiologically relevant conditions, reducing reliance on animal studies. Furthermore, expanding theranostic technologies will enable real-time monitoring of drug biodistribution, therapeutic response, and disease progression through integrated imaging capabilities. Collectively, these future directions pave the way toward more effective, safer, and customizable neurotherapeutic strategies<sup>38-39</sup>.

## 11. Conclusion

BBB-targeted nanotechnology has emerged as one of the most promising frontiers in neurotherapeutics, offering novel solutions to longstanding challenges in delivering drugs to the central nervous system. Advances in polymeric, lipid-based, inorganic, biomimetic, and hybrid nanocarriers have demonstrated significant potential to enhance brain penetration, improve therapeutic efficacy, and enable multimodal treatment approaches. While hurdles related to translation, safety, manufacturing, and regulation remain, ongoing innovations—such as AI-guided design, next-generation BBB models, and adaptive nanoplatforms—are steadily closing the gap between laboratory research and clinical application. With continued multidisciplinary collaboration, nanotechnology is positioned to reshape the future of CNS medicine, paving the way for more precise, effective, and accessible treatments for neurodegenerative diseases, cancers, and other debilitating neurological disorders.

## References

1. Barnabas, W. K. (2018). Drug targeting strategies into the brain for treating neurological diseases. *Journal of Neuroscience Methods*, 311, 133–146.
2. Di Luca, M., Nutt, D., Oertel, W., Boyer, P., Jaarsma, J., Destrebecq, F., Esposito, G., & Quoidbach, V. (2018). Towards earlier diagnosis and treatment of disorders of the brain. *Bulletin of the World Health Organization*, 96, 298A.
3. Dong, X. (2018). Current strategies for brain drug delivery. *Theranostics*, 8, 1481–1493.
4. Mo, X., Liu, E., & Huang, Y. (2019). The intra-brain distribution of brain targeting delivery systems. In H. Gao & X. Gao (Eds.), *Brain targeted drug delivery system* (pp. 409–438). Academic Press.
5. Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018). Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. *Journal of Controlled Release*, 281, 139–177.
6. Shatzmiller, S., Lapidot, I., & Zats, G. (2016). Blood brain barrier crossing for therapeutic and diagnostic agents. *SM Journal of Neurological Disorders and Stroke*, 2, 1012.
7. Alexander, J. J. (2018). Blood–brain barrier (BBB) and the complement landscape. *Molecular Immunology*, 102, 26–31.
8. Patel, M. M., & Patel, B. M. (2017). Crossing the blood–brain barrier: Recent advances in drug delivery to the brain. *CNS Drugs*, 31, 109–133.

9. Hersh, D. S., Wadajkar, A. S., Roberts, N., Perez, J. G., Connolly, N. P., Frenkel, V., Winkles, J. A., Woodworth, G. F., & Kim, A. J. (2016). Evolving drug delivery strategies to overcome the blood–brain barrier. *Current Pharmaceutical Design*, 22, 1177–1193.
10. Çetin, M., Aytekin, E., Yavuz, B., & Bozdağ-Pehlivan, S. (2017). Nanoscience in targeted brain drug delivery. In Y. Gürsoy-Özdemir, S. Bozdağ-Pehlivan, & E. Sekerdag (Eds.), *Nanotechnology methods for neurological diseases and brain tumors* (pp. 117–147). Academic Press.
11. Ayodele, A. T., Valizadeh, A., Adabi, M., Esnaashari, S. S., Madani, F., Khosravani, M., & Adabi, M. (2017). Ultrasound nanobubbles and their applications as theranostic agents in cancer therapy: A review. *Biointerface Research in Applied Chemistry*, 7, 2253–2262.
12. Faisal, N., & Kumar, K. (2017). Polymer and metal nanocomposites in biomedical applications. *Biointerface Research in Applied Chemistry*, 7, 2286–2294.
13. Husain, Q. (2017). Nanosupport bound lipases: Their stability and applications. *Biointerface Research in Applied Chemistry*, 7, 2194–2216.
14. Kaur, M., Singh, G., Khanna, K., & Kaur, N. (2015). Nanotechnology: A review. In *Proceedings of the Second National Conference on Advances in Manufacturing Systems*, SBS State Technical Campus, Ferozepur, India, December 23–24.
15. Abou El Ela, A. E. S. F., El Khatib, M. M., & Salem-Bekhit, M. M. (2017). Design, characterization and microbiological evaluation of microemulsion-based gel of griseofulvin for topical delivery. *Biointerface Research in Applied Chemistry*, 7, 2277–2285.
16. Davoodi, S. D., & Saghavaz, B. H. (2017). Optimal synthesis and characterization of magnetic CuMnFe<sub>2</sub>O<sub>4</sub> nanoparticles coated by PEG for drug delivery. *Biointerface Research in Applied Chemistry*, 7, 2249–2252.
17. Pignatello, R., Fuochi, V., Petronio, G. P., Greco, A. S., & Furneri, P. M. (2017). Formulation and characterization of erythromycin-loaded solid lipid nanoparticles. *Biointerface Research in Applied Chemistry*, 7, 2145–2150.
18. Fonseca-Santos, B., Gremião, M. P. D., & Chorilli, M. (2015). Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. *International Journal of Nanomedicine*, 10, 4981–5003.
19. Shah, K., & Abbruscato, T. (2017). The blood–brain barrier. In P. M. Conn (Ed.), *Conn's translational neuroscience* (pp. 141–146). Academic Press.
20. Obermeier, B., Verma, A., & Ransohoff, R. M. (2016). The blood–brain barrier. In S. J. Pittock & A. Vincent (Eds.), *Handbook of clinical neurology* (Vol. 133, pp. 39–59). Elsevier.
21. Khanna, A. K., & Farag, E. (2017). Blood–brain barrier. In H. Prabhakar (Ed.), *Essentials of neuroanesthesia* (pp. 51–58). Academic Press.
22. Quintana, F. J. (2017). Astrocytes to the rescue! Glia limitans astrocytic endfeet control CNS inflammation. *Journal of Clinical Investigation*, 127, 2897–2899.

23. Engelhard, H. H., Arnone, G. D., Mehta, A. I., & Nicholas, M. K. (2018). Biology of the blood–brain and blood–brain tumor barriers. In H. B. Newton (Ed.), *Handbook of brain tumor chemotherapy, molecular therapeutics, and immunotherapy* (2nd ed., pp. 113–125). Academic Press.
24. Gürsoy-Özdemir, Y., & Tas, Y. C. (2017). Anatomy and physiology of the blood–brain barrier. In Y. Gürsoy-Özdemir, S. Bozdağ-Pehlivan, & E. Sekerdag (Eds.), *Nanotechnology methods for neurological diseases and brain tumors* (pp. 3–13). Academic Press.
25. Gupta, S., Dhanda, S., & Sandhir, R. (2019). Anatomy and physiology of the blood–brain barrier. In H. Gao & X. Gao (Eds.), *Brain targeted drug delivery system* (pp. 7–31). Academic Press.
26. Lindauer, U. (2017). Physiology of cerebral blood vessels. In J. Badaut & N. Plesnila (Eds.), *Brain edema* (pp. 3–27). Academic Press.
27. Greene, C., & Campbell, M. (2016). Tight junction modulation of the blood–brain barrier: CNS delivery of small molecules. *Tissue Barriers*, 4, e1138017.
28. Mishra, A., Attwell, D., Hall, C., O’Farrell, F., & Dalkara, T. (2016). What is a pericyte? *Journal of Cerebral Blood Flow & Metabolism*, 36, 451–455.
29. Chen, Z.-Y., Gu, X.-D., & Zang, Y.-W. (2015). Brain metastasis of colorectal cancer: Microenvironment and molecular mechanism. In M. A. Hayat (Ed.), *Brain metastases from primary tumors* (pp. 191–202). Academic Press.
30. Tajés, M., Ramos-Fernandez, E., Weng-Jiang, X., Bosch-Morato, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernandez-Busquets, X., Roquer, J., & Munoz, F. J. (2014). The blood–brain barrier: Structure, function and therapeutic approaches to cross it. *Molecular Membrane Biology*, 31, 152–167.
31. **Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D.** (2006). Blood–brain barrier: Structural components and function under physiologic and pathologic conditions. *Journal of Neuroimmune Pharmacology*, 1, 223–236.
32. **Barar, J., Rafi, M. A., Pourseif, M. M., & Omid, Y.** (2016). Blood–brain barrier transport machineries and targeted therapy of brain diseases. *BioImpacts*, 6, 225–248.
33. **Li, G., Shao, K., & Umeshappa, C. S.** (2019). Recent progress in blood–brain barrier transportation research. In H. Gao & X. Gao (Eds.), *Brain targeted drug delivery system* (pp. 33–51). Academic Press.
34. **Erickson, M. A., & Banks, W. A.** (2018). Neuroimmune axes of the blood–brain barriers and blood–brain interfaces: Bases for physiological regulation, disease states, and pharmacological interventions. *Pharmacological Reviews*, 70, 278–314.
35. **He, Q., Liu, J., Liang, J., Liu, X., Li, W., Liu, Z., Ding, Z., & Tuo, D.** (2018). Towards improvements for penetrating the blood–brain barrier—Recent progress from a material and pharmaceutical perspective. *Cells*, 7(3), 24.
36. **Di, L., & Kerns, E. H.** (2016). Blood–brain barrier. In L. Di & E. H. Kerns (Eds.), *Drug-like properties* (2nd ed., pp. 141–159). Academic Press.

37. **O’Keeffe, E., & Campbell, M.** (2016). Modulating the paracellular pathway at the blood–brain barrier: Current and future approaches for drug delivery to the CNS. *Drug Discovery Today: Technologies*, 20, 35–39.
38. **Ali, I. U., & Chen, X.** (2015). Penetrating the blood–brain barrier: Promise of novel nanoplateforms and delivery vehicles. *ACS Nano*, 9, 9470–9474.
39. **Takechi, R., Fakhoury, M., & Al-Salami, H.** (2015). Drug permeation across the blood–brain barrier: Applications of nanotechnology. *British Journal of Medicine and Medical Research*, 6, 547–556.